Intestinal absorption and models of penetration

Solubility, Delivery and ADME Problems of Drugs and Drug-Candidates

Volumn , Issue , 2011, Pages 86-101

  Hellinger, Eva ^a   Vastag, Monika ^a  

^a GEDEON RICHTER LTD   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84867847828     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.2174/978160805120511101010086     Document Type: Chapter

References (122)

1. Zhao YH, Le J, Abraham MH, et al. Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors. J Pharm Sci 2001, 90: 749-84.
2. Lennernäs H. Human jejunal effective permeability and its correlation with preclinical drug absorption models. J Pharm Pharmacol 1997, 49(7): 627-38.
3. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000, 44(1): 235-49.
4. Veber DF. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002, 45(12): 2615-23.
5. Dahan AS, Amidon GL. Gastrointestinal dissolution and absorption of class II drugs. In: Waterbeemd H, Testa B, Eds. Drug bioavailability. Weinheim: Wiley VCH, 2009; pp. 191-215).
6. Kaminsky LS, Zhang Q. The small intestine as a xenobiotic-metabolizing organ. Drug Metab Dispos 2003, 31(12): 1520-5.
7. Iatropoulos MJ. Morphology of the gastrointestinal tract. In: Rozman K, Hannen O, Eds. Gastrointestinal toxicology. Amsterdam, Elsevier, 1986; pp. 246-66.
8. Lin JH, Chiba M, Baillie TA. 'Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 1999; 51(2): 135-58.
9. Avdeef A, Tam KY. How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability? J Med Chem 2010; 53(9): 3566-84.
10. Barrett KE, Barman SM, Boitano S, Brooks, HL. Ganong's Review of medical physiology. Lange, Singapore, McGraw- Hill Medical, 2010
11. Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug. Adv Drug Deliv Rev 2001; 50 Suppl 1: S41-67.
12. Fallinborg J, Christensen LA, Ingeman-Nielsen M, Jacobsen BA, Abildgaard K, Rasmussen, HH. pH-profile and regional transit times of the normal gut measured by a radiotelemetry device. Aliment Pharmacol Ther 1989, 3(6): 605-13.
13. Didziapetris R, Japertas P, Avdeef A, Petrauskas AJ. Classification analysis of P-glycoprotein substrate specificity. Drug Target 2003, 11(7): 391-406.
14. Mouly S, Paine MF. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res 2003, 20(10): 1595-9.
15. Paine MF, Khalighi M, Fisher JM, et al. Characterisation of intestinal and intraintestinal variations in human CYP3A4- dependent metabolism. J Pharmacol Exp Ther 1997, 283(3): 1552-62.
16. Paine MF, Hartm HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. The human intestinal cytochrome P450 "pie". Drug Metab Dispos 2006, 34(5): 880-6.
17. Metcalfe PD, Thomas S. Challenges in the prediction and modeling of oral absorption and bioavailability. Curr Opin Drug Discov Devel 2010, 13(1): 104-10.
18. Hou T, Li Y, Zhang W, Wang J. Recent developments of in silico predictions of intestinal absorption and oral bioavailability. Comb Chem High Throughput Screen 2009, 12(5): 497-506.
19. Dokoumetzidis A, Kalantzi L, Fotaki N. Predictive models for oral drug absorption: from in silico methods to integrated dynamical models. Expert Opin Drug Metab Toxicol 2007, 3(4): 491-505.
20. Wang J, Skolnik S. Mitigating permeability-mediated risks in drug discovery. Expert Opin Drug Metab Toxicol 2010, 6(2): 171-87.
21. Hämäläinen MD, Frostell-Karlsson A. Predicting the intestinal absorption potential of hits and leads. Drug Discov Today:Technologies 2004, 1(4): 397-405.
22. Vastag M, Keseru GM. Current in vitro and in silico models of blood-brain barrier penetration: a practical view. Curr Opin Drug Discov Devel 2009, 12(1): 115-24.
23. Ponce YM, Pérez MAC, Zaldivar VR, Sanz MB, Mota DS, Torrens F. Prediction of intestinal epithelial transport of drug in (Caco-2) cell culture from molecular structure using in silico approaches during early drug discovery. Internet Electron J Mol Des 2005; 4: 124-150. Available from: http://www.biochempress.com.
24. Palm K, Stenberg P, Luthman K, Artursson P. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm Res 1997, 14(5): 568-71.
25. Clark DE. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. J Pharm Sci 1999, 88(8): 807-14.
26. Demel MA, Schwaha R, Krämer O, Ettmayer P, Haaksma EE, Ecker GF. In silico prediction of substrate properties for ABC-multidrug transporters. Expert Opin Drug Metab Toxicol 2008, 4(9): 1167-80.
27. Winiwarter S, Hilgendorf C. Modeling of drug-transporter interactions using structural information. Curr Opin Drug Discov Devel 2008, 11(1): 95-103.
28. Corti G, Maestrelli F, Cirri M, Zerrouk N, Mura P. Development and evaluation of an in vitro method for prediction of human drug absorption II. Demonstration of the method suitability. Eur J Pharm Sci 2006, 27(4): 354-62.
29. Corti G, Maestrelli F, Cirri M, Furlanetto S, Mura P. Development and evaluation of an in vitro method for prediction of human drug absorption I. Assessment of artificial membrane composition. Eur J Pharm Sci 2006, 27(4): 346-53.
30. Danelian E, Karlén A, Karlsson R, et al. SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans. J Med Chem 2000, 43(11): 2083-6.
31. Pidgeon C, Ong S, Liu H, et al. IAM chromatography: an in vitro screen for predicting drug membrane permeability. J Med Chem 1995, 38(4): 590-4.
32. Caldwell GW, Masucci JA, Evangelisto M, White R. Evaluation of the immobilized artificial membrane phosphatidylcholine. Drug discovery column for high-performance liquid chromatographic screening of drug-membrane interactions. J Chromatogr A 1998, 800(2): 161-9.
33. Ong S, Liu H, Pidgeon C. Immobilized-artificial-membrane chromatography: measurements of membrane partition coefficient and predicting drug membrane permeability. J Chromatogr A 1996; 728(1-2): 113-28.
34. Hidalgo IJ. Assessing the absorption of new pharmaceuticals. Curr Top Med Chem 2001, 1(5): 385-401.
35. Stavchansky S, Berndt C. Experimental and theoretical methods to study drug permeability. In: Amidon G, Lesko L, Midha K, Shah V, Hilfinger J, editors. International bioequivalence standards: A new era. Ann Arbor, TSRL Inc., 2006; pp. 49-115.
36. Kansy M, Senner F, Gubernator K. Physicochemical high throughput screening: parallel artificial membrane permeationassay in the description of passive absorption processes. J Med Chem 1998, 41(7): 1007-10.
37. Avdeef A, Bendels S, Di L, Faller B, Kansy M, Sugano K, Yamauchi Y. PAMPA-critical factors for better predictions of absorption. J Pharm Sci 2007, 96(11): 2893-909.
38. Zhu C, Jiang L, Chen TM, Hwang KK. A comparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential. Eur J Med Chem 2002, 37(5): 399-407.
39. Faller B. Artificial membrane assays to assess permeability. Curr Drug Metab 2008, 9(9): 886-92.
40. Kansy M, Avdeef A, Fischer H. Advances in screening for membrane permeability: High-resolution PAMPA for medical chemists. Drug Discov Today:Technologies 2004, 1(4): 349-355.
41. Balimane PV, Chong S, Morrison RA. Current methodologies used for evaluation of intestinal permeability and absorption. J Pharmacol Toxicol Methods 2000, 44(1): 301-12.
42. Moyer MP. Culture of human gastrointestinal epithelial cells. Proc Soc Exp Biol Med 1983, 174(1): 12-5.
43. Mahida YR, Makh S, Hyde S, Gray T, Borriello SP. Effect of Clostridium difficile toxin A on human intestinal epithelial cells: induction of interleukin 8 production and apoptosis after cell detachment. Gut 1996, 38(3): 337-47.
44. Ungell A L. Caco-2 replace or refine? Drug Discov Today: Technol 2004; 1: 423-30.
45. Hubatsch I, Ragnarsson EG, Artursson P,. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat Protoc 2007, 2: 2111-9.
46. Delie F, Rubas W. A human colonic cell line sharing similarities with enterocytes as a model to examine oral absorption: advantages and limitations of the Caco-2 model. Crit Rev Ther Drug Carrier Syst 1997, 14(3): 221-86.
47. Anderle P, Rakhmanova V, Woodford K, Zerangue N, Sadée W. Messenger RNA expression of transporter and ion channel genes in undifferentiated and differentiated Caco-2 cells compared to human intestines. Pharm Res 2003, 20: 3-15.
48. Sun D, Lennernas H, Welage LS, et al. Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res 2002, 19: 1400-16.
49. Seithel A, Karlsson J, Hilgendorf C, Björquist A, Ungell AL. Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells. Eur J Pharm Sci 2006, 28: 291-9.
50. Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 2001, 46: 27-43.
51. Lennernäs H. Human intestinal permeability. J Pharm Sci 1998, 87(4): 403-10.
52. Skolnik S, Lin X, Wang J, Chen XH, He T, Zhang B. Towards prediction of in vivo intestinal absorption using a 96-well Caco-2 assay. J Pharm Sci. 2010, 99(7): 3246-65.
53. Huang J, Si L, Jiang L, Fan Z, Qiu J, Li G. Effect of pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism. Int J Pharm. 2008; 356(1-2): 351-3.
54. Anderle P, Niederer E, Rubas W, et al. P-Glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: the influence of culturing conditions and drug exposure on P-gp expression levels. J Pharm Sci 1998, 87: 757-62.
55. Behrens I, Kissel T. Do cell culture conditions influence the carrier-mediated transport of peptides in Caco-2 cell monolayers? Eur J Pharm Sci 2003; 19: 433-42.
56. Prueksaritanont T, Gorham LM, Hochman JH, Tran LO, Vyas KP. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. Drug Metab Dispos 1996, 24: 634-42.
57. Korjamo T, Mönkkönen J, Uusitalo J, Turpeinen M, Pelkonen O, Honkakoski P. Metabolic and efflux properties of Caco- 2 cells stably transfected with nuclear receptors. Pharm Res 2006, 23: 1991-2001.
58. Lampen A, Bader A, Bestmann T, Winkler M, Witte L, Borlak JT. Catalytic activities, protein- and mRNA-expression of cytochrome P450 isoenzymes in intestinal cell lines. Xenobiotica 1998, 28(5): 429-441.
59. Sun H, Chow EC, Liu S, Du Y, Pang KS. The Caco-2 cell monolayer: usefulness and limitations. Expert Opin Drug Metab Toxicol 2008, 4(4): 395-411.
60. Chong S, Dando SA, Soucek KM, Morrison RA. In vitro permeability through caco-2 cells is not quantitatively predictive of in vivo absorption for peptide-like drugs absorbed via the dipeptide transporter system. Pharm Res 1996, 13(1): 120-3.
61. Balimane PV, Han YH, Chong S.. Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS J. 2006; 8: E1-13.
62. Lentz KA, Hayashi J, Lucisano LJ, Polli JE. Development of a more rapid, reduced serum culture system for Caco-2 monolayers and application to the biopharmaceutics classification system. Int J Pharm 2000, 200: 41-51.
63. Liang E, Chessic K, Yazdanian M. Evaluation of an accelerated Caco-2 cell permeability model. J Pharm Sci 2000, 89: 336-45.
64. Uchida M, Fukazawa T, Yamazaki Y, Hashimoto H, Miyamoto Y. A modified fast (4 day) 96-well plate Caco-2 permeability assay. J Pharmacol Toxicol Methods 2009, 59: 39-43.
65. Yamashita S, Konishi K, Yamazaki Y, Taki Y, Sakane T, Sezaki H, Furuyama Y. New and better protocols for a shortterm Caco-2 cell culture system. J Pharm Sci 2002, 91(3): 669-79.
66. Mariadason JM, Rickard KL, Barkla DH, Augenlicht LH, Gibson PR. Divergent phenotypic patterns and commitment to apoptosis of Caco-2 cells during spontaneous and butyrate-induced differentiation. J Cell Physiol 2000, 183: 347-54.
67. Horie K, Tang F, Borchardt RT. Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter. Pharm Res 2003, 20: 161-8.
68. Korjamo T, Honkakoski P, Toppinen MR, et al. Absorption properties and P-glycoprotein activity of modified Caco-2 cell lines. Eur J Pharm Sci 2005, 26: 266-79.
69. Shirasaka Y, Kawasaki M, Sakane T, et al. Induction of human P-glycoprotein in Caco-2 cells: development of a highly sensitive assay system for P-glycoprotein-mediated drug transport. Drug Metab Pharmacokinet 2006, 21: 414-23.
70. Shirasaka Y, Sakane T, Yamashita S. Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane. J Pharm Sci 2008, 97: 553-65.
71. Siissalo S, Laitinen L, Koljonen M, Vellonen KS, Kortejärvi H, Urtti A, Hirvonen J, Kaukonen AM. Effect of cell differentiation and passage number on the expression of efflux proteins in wild type and vinblastine-induced Caco-2 cell lines. Eur J Pharm Biopharm 2007, 67: 548-54.
72. Döppenschmitt S, Spahn-Langguth H, Regårdh CG, Langguth P. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein. J Pharm Sci 1999, 88: 1067-72.
73. Hellinger E, Bakk ML, Pócza P, Tihanyi K, Vastag M. Drug penetration model of vinblastine-treated Caco-2 cultures. Eur J Pharm Sci 2010, 41(1): 96-106.
74. Wils P, Warnery A, Phung-Ba V, Scherman D. Differentiated intestinal epithelial cell lines as in vitro models for predicting the intestinal absorption of drugs. Cell Biol Toxicol 1994; 10(5-6): 393-7.
75. Wikman A, Karlsson J, Carlstedt I, Artursson P. A drug absorption model based on the mucus layer producing human intestinal goblet cell line HT29-H. Pharm Res 1993, 10(6): 843-52.
76. Barthe L, Woodley J, Houin G. Gastrointestinal absorption of drugs: methods and studies. Fundam Clin Pharmacol 1999, 13(2): 154-68.
77. Haslam IS, Jones K, Coleman T, Simmons NL. Induction of P-glycoprotein expression and function in human intestinal epithelial cells (T84). Biochem Pharmacol 2008, 76(7): 850-61.
78. Volpe DA. Variability in Caco-2 and MDCK cell-based intestinal permeability assays. J Pharm Sci. 2008, 97: 712-25.
79. Irvine JD, Takahashi L, Lockhart K, et al. MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci 1999, 88(1): 28-33.
80. Wang Q, Rager JD, Weinstein K, et al. Evaluation of the MDR-MDCK cell line as a permeability screen for the bloodbrain barrier. Int J Pharm 2005, 288(2): 349-59.
81. Tavelin S, Milovic V, Ocklind G, Olsson S, Artursson P. A conditionally immortalized epithelial cell line for studies of intestinal drug transport. J Pharmacol Exp Ther 1999, 290(3): 1212-21.
82. Fisher RB, Parsons DS. A preparation of surviving rat small intestine for the study of absorption. J Physiol 1949, 110: 36-46.
83. Quastel JH. Technics for studies of intestinal absorption in vitro. Methods Med Res 1961, 9: 273-86.
84. Andlauer W, Kolb J, Stehle P, Fürst P. Absorption and metabolism of genistein in isolated rat small intestine. J Nutr 2000, 130(4): 843-6.
85. Plauth M, Raible A, Bauder-Gross D, Vieillard-Baron D, Fürst P, Hartmann F. Effects of dexamethasone on glutamine metabolism in the isolated vascularly perfused rat small intestine. Res Exp Med (Berl). 1991, 191(5): 349-57.
86. Wei Y, Neves LA, Franklin T, Klyuchnikova N, Placzek B, Hughes HM, Curtis CG. Vascular perfused segments of human intestine as a tool for drug absorption. Drug Metab Dispos. 2009, 37(4): 731-6.
87. Hillgren KM, Kato A, Borchardt RT. In vitro systems for studying intestinal drug absorption. Med Res Rev 1995, 15(2): 83-109.
88. Le Ferrec E, Chesne C, Artusson P, et al. In vitro models of the intestinal barrie. The report and recommendations of ECVAM Workshop 46. European Centre for the Validation of Alternative methods. Altern Lab Anim 2001, 29(6): 649-68.
89. Carreño-Gómez B, Duncan R. Everted rat intestinal sacs: a new model for the quantitation of P-glycoprotein mediatedefflux of anticancer agents. Anticancer Res 2000; 20(5A): 3157-61.
90. Barthe L, Woodley J, Houin G. Gastrointestinal absorption of drugs: methods and studies. Fundam Clin Pharmacol 1999, 13(2): 154-68.
91. Leppert PS, Fix JA. Use of everted intestinal rings for in vitro examination of oral absorption potential. J Pharm Sci 1994, 83(7): 976-81.
92. Barthe L, Woodley JF, Kenworthy S, Houin G. An improved everted gut sac as a simple and accurate technique to measure paracellular transport across the small intestine. Eur J Drug Metab Pharmacokinet 1998, 23(2): 313-23.
93. Lacombe O, Woodley J, Solleux C, Delbos JM, Boursier-Neyret C, Houin G. Localisation of drug permeability along the rat small intestine, using markers of the paracellular, transcellular and some transporter routes. Eur J Pharm Sci 2004; 23(4-5): 385-91.
94. Ballent M, Lifschitz A, Virkel G, Sallovitz J, Lanusse C. Modulation of the P-glycoprotein-mediated intestinal secretion of ivermectin: in vitro and in vivo assessments. Drug Metab Dispos 2006, 34(3): 457-63.
95. Bouër R, Barthe L, Philibert C, Tournaire C, Woodley J, Houin G. The roles of P-glycoprotein and intracellular metabolism in the intestinal absorption of methadone: in vitro studies using the rat everted intestinal sac. Fundam Clin Pharmacol 1999, 13(4): 494-500.
96. Lafforgue G, Arellano C, Vachoux C, et al. Oral absorption of ampicillin: role of paracellular route vs. PepT1 transporter. Fundam Clin Pharmacol 2008, 22(2): 189-201.
97. Arellano C, Philibert C, Vachoux C, Woodley J, Houin G. The metabolism of midazolam and comparison with other CYP enzyme substrates during intestinal absorption: in vitro studies with rat everted gut sacs. J Pharm Pharm Sci 2007, 10(1): 26-36.
98. Quevedo MA, Briñón MC. In vitro and in vivo pharmacokinetic characterization of two novel prodrugs of zidovudine. Antiviral Res 2009, 83(2): 103-11.
99. Maeda Y, Omoda K, Konishi T, et al. Effects of aluminium-containing antacid on bioavailability of ofloxacin following oral administration of pivaloyloxymethyl ester of ofloxacin as prodrug. Biol Pharm Bull 1993, 16(6): 594-9.
100. Yang CY, Chao PD, Hou YC, Tsai SY, Wen KC, Hsiu SL. Marked decrease of cyclosporin bioavailability caused by coadministration of ginkgo and onion in rats. Food Chem Toxicol 2006, 44(9): 1572-8.
101. Huang, S.M., Strong, J.M., Zhang, L., et al. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 2008; 48: 662-70.
102. Cornaire G, Woodley JF, Saivin S, Legendre JY, Decourt S, Cloarec A, Houin G. Effect of polyoxyl 35 castor oil and Polysorbate 80 on the intestinal absorption of digoxin in vitro. Arzneimittelforschung 2000, 50(6): 576-9.
103. Ussing HH, Zerahn K. Active transport of sodium as the source of electric current in the short-circuited isolated frog skin. Acta Physiol Scand 1951; 23(2-3): 110-27
104. Clarke LL. A guide to Ussing chamber studies of mouse intestine. Am J Physiol Gastrointest Liver Physiol. 2009; 296(6): G1151-66.
105. Wallon C, Braaf Y, Wolving M, Olaison G, Söderholm JD. Endoscopic biopsies in Ussing chambers evaluated for studies of macromolecular permeability in the human colon. Scand J Gastroenterol 2005, 40(5): 586-95.
106. Matysiak-Budnik T, Coffin B, Lavergne-Slove A, Sabate JM, Mégraud F, Heyman M. Helicobacter pylori increases the epithelial permeability to a food antigen in human gastric biopsies. Am J Gastroenterol 2004, 99(2): 225-32.
107. 107. Mardones P, Andrinolo D, Csendes A, Lagos N. Permeability of human jejunal segments to gonyautoxins measured by the Ussing chamber technique. Toxicon 2004, 44(5): 521-8.
108. van de Kerkhof EG, Ungell AL, Sjöberg AK, et al. Innovative methods to study human intestinal drug metabolism in vitro: precision-cut slices compared with ussing chamber preparations. Drug Metab Dispos 2006, 34(11): 1893-902.
109. Nishimura T, Amano N, Kubo Y, et al. Asymmetric intestinal first-pass metabolism causes minimal oral bioavailability of midazolam in cynomolgus monkey. Drug Metab Dispos 2007, 35(8): 1275-84.
110. Bohets H, Annaert P, Mannens G, et al. Strategies for absorption screening in drug discovery and development. Curr Top Med Chem 2001, 1(5): 367-83.
111. Kikuchi A, Nozawa T, Wakasawa T, Maeda T, Tamai I. Transporter-mediated intestinal absorption of fexofenadine in rats. Drug Metab Pharmacokinet 2006, 21(4): 308-14.
112. Sugiyama T, Yamamoto A, Kawabe Y, Uchiyama T, Quan YS, Muranishi S. Effects of various absorption enhancers on the intestinal absorption of water soluble drugs by in vitro Ussing chamber method: correlation with an in situ absorption experiment. Biol Pharm Bull 1997, 20(7): 812-4.
113. Jezyk N, Rubas W, Grass GM. Permeability characteristics of various intestinal regions of rabbit, dog and monkey. Pharm Res 1992, 9(12): 1580-1586.
114. Kaddoumi A, Fleisher D, Heimbach T, Li LY, Cole S. Factors influencing regional differences in intestinal absorption of UK-343,664 in rat: possible role in dose-dependent pharmacokinetics. J Pharm Sci 2006, 95(2): 435-45.
115. Sababi M, Borgå O, Hultkvist-Bengtsson U. The role of P-glycoprotein in limiting intestinal regional absorption of digoxin in rats. Eur J Pharm Sci 2001, 14(1): 21-7.
116. Song NN, Li QS, Liu CX. Intestinal permeability of metformin using single-pass intestinal perfusion in rats. World J Gastroenterol 2006, 12(25): 4064-70.
117. Blanchard J, Tang LM, Earle ME. Reevaluation of the absorption of carbenoxolone using an in situ rat intestinal technique. J Pharm Sci 1990, 79(5): 411-4.
118. Yuasa H, Matsuda K, Watanabe J. Influence of anesthetic regimens on intestinal absorption in rats. Pharm Res 1993, 10(6): 884-8.
119. Uhing MR, Kimura RE. The effect of surgical bowel manipulation and anesthesia on intestinal glucose absorption in rats. J Clin Invest 1995, 95(6): 2790-8.
120. de Zwart LL, Rompelberg CJM, Sips AJAM, Welink J, van Engelen JGM. Anatomical and physiological differences between various species used in studies on the pharmacokinetics and toxicology of xenobiotics. A review of literature. National Institute of Public Health and the Environment, RIVM, Bilthoven, The Netherlands 1999. (http://www.rivm.nl/bibliotheek/rapporten/623860010.html)
121. He YL, Murby S, Warhurst G, et al. Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides. J Pharm Sci 1998, 87: 626-633.
122. DeSesso JM, Jacobson CF. Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. Food Chem Toxicol 2001, 39(3): 209-28.